Ejection Fraction
Researchers develop prediction model for adverse cardiac events in mitochondrial diseases
Researchers have developed the first prediction model for the prediction of HF- and arrhythmia-related major adverse cardiac events in patients with mitochondrial diseases.
DELIVER: Dapagliflozin cuts risk for worsening HF in adults with, without type 2 diabetes
Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.
In initial assessment of cardiac function by echocardiography, AI bests sonographers
In adults being evaluated for cardiac function by echocardiography, an initial assessment of left ventricular ejection fraction by artificial intelligence was superior to an assessment by a sonographer, researchers reported.
In low-income countries, reduced LVEF common in STEMI, confers poor outcomes
In a cohort of patients with STEMI in India, reduced left ventricular ejection fraction was common and associated with mortality, and medication adherence at 1 year was low, researchers reported.
Hemodynamic support appears to improve LV ejection fraction in high-risk PCI
Among patients undergoing high-risk PCI with mechanical circulatory support who survived to 90 days without further major cardiac complications, many had improved left ventricular ejection fraction, according to data from RESTORE EF.
DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%
Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.
Video: SGLT2 inhibitors ‘gaining momentum’ in heart failure treatment
In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from the American College of Cardiology Scientific Session
Video: ‘Language matters’ in new HF guidelines
In this video, Anu Lala, MD, associate professor of medicine (cardiology) at Icahn School of Medicine at Mount Sinai, discusses new HF developments stemming from the American College of Cardiology Scientific Session.
Outcomes differ in patients with coexisting COPD and heart failure, based on phenotype
Outcomes among patients with coexisting COPD and heart failure with preserved ejection fraction were largely driven by COPD, with more acute exacerbations than in those with other types of heart failure, researchers reported.
VIDEO: AHA presentations provide updates on SGLT2 inhibitors in HF
In this video, Javed Butler, MD discusses research on SGLT2 inhibitors presented at the American Heart Association Scientific Sessions.